The Cytomegalovirus Infection Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
“Cytomegalovirus Infection Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Cytomegalovirus Infection Market.
Some of the key takeaways from the Cytomegalovirus Infection Pipeline Report:
-
Companies across the globe are diligently working toward developing novel Cytomegalovirus Infection treatment therapies with a considerable amount of success over the years.
-
Cytomegalovirus Infection companies working in the treatment market are antiviral therapeutics TSRL, Synklino, AlloVir, Moderna, China Immunotech, Nobelpharma, Hookipa Biotech GmbH, Biotest, AlloVir, VBI Vaccines, Lion TCR, Shire, Merck Sharp & Dohme, Takeda, CSL Behring, Chimerix, Novartis, Hookipa Biotech GmbH, and others, are developing therapies for the Cytomegalovirus Infection treatment
-
Emerging Cytomegalovirus Infection therapies in the different phases of clinical trials are- Research programme, SYN002, Posoleucel, mRNA-1647, CMV TCR T cell therapy, NPC-21, HB-101, Cytomegalovirus immune globulin, Posoleucel, VBI-1501A, LTV 20, Maribavir, V160, Maribavir, Valganciclovir, Brincidofovir, Everolimus, HB-101 vaccine, and others are expected to have a significant impact on the Cytomegalovirus Infection market in the coming years.
-
In February 2024, A novel mRNA vaccine currently undergoing phase 3 clinical trials demonstrates superior efficacy in stimulating the immune system to combat cytomegalovirus infection. This experimental mRNA vaccine targeting human cytomegalovirus (CMV), a prevalent virus with potential prenatal transmission, has elicited highly encouraging immune responses compared to other CMV vaccine candidates, as per research conducted by investigators from Weill Cornell Medicine.
-
In June 2023, The FDA sanctioned letermovir for shielding adult kidney transplant recipients at elevated risk (where the donor has CMV antibodies and the recipient does not). Letermovir, a novel non-nucleoside medication, is the first of its kind designed to impede viral replication by specifically targeting the viral terminase complex.
Cytomegalovirus Infection Overview
Cytomegalovirus Infection is a common viral infection caused by the cytomegalovirus, a type of herpes virus. CMV is widespread and can infect people of all ages. In healthy individuals with intact immune systems, CMV infection often causes mild or no symptoms and may go unnoticed. However, in individuals with weakened immune systems, such as those with HIV/AIDS, organ transplant recipients, or infants infected in utero, CMV infection can lead to more severe complications.
Get a Free Sample PDF Report to know more about Cytomegalovirus Infection Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/cytomegalovirus-cmv-infection-pipeline-insight
Emerging Cytomegalovirus Infection Drugs Under Different Phases of Clinical Development Include:
-
Research programme: antiviral therapeutics TSRL
-
SYN002: Synklino
-
Posoleucel: AlloVir
-
mRNA-1647: Moderna
-
CMV TCR T cell therapy: China Immunotech
-
NPC-21: Nobelpharma
-
HB-101: Hookipa Biotech GmbH
-
Cytomegalovirus immune globulin: Biotest
-
Posoleucel: AlloVir
-
VBI-1501A: VBI Vaccines
-
LTV 20: Lion TCR
-
Maribavir: Shire
-
V160: Merck Sharp & Dohme
-
Maribavir: Takeda
-
Valganciclovir: CSL Behring
-
Brincidofovir: Chimerix
-
Everolimus: Novartis
-
HB-101 vaccine: Hookipa Biotech GmbH
Cytomegalovirus Infection Route of Administration
Cytomegalovirus Infection pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
-
Intranasal
-
Intrathecal
-
Intravenous
-
Oral
-
Oral/Intravenous
-
Parenteral
-
Subcutaneous
-
Subcutaneous/Intramuscular
-
Transdermal
Cytomegalovirus Infection Molecule Type
Cytomegalovirus Infection Products have been categorized under various Molecule types, such as
-
Antisense oligonucleotide
-
Gene therapy
-
Hormones
-
Neuropeptides
-
Oligonucleotides
-
Small Molecule
-
Triglyceride
Cytomegalovirus Infection Pipeline Therapeutics Assessment
-
Cytomegalovirus Infection Assessment by Product Type
-
Cytomegalovirus Infection By Stage and Product Type
-
Cytomegalovirus Infection Assessment by Route of Administration
-
Cytomegalovirus Infection By Stage and Route of Administration
-
Cytomegalovirus Infection Assessment by Molecule Type
-
Cytomegalovirus Infection by Stage and Molecule Type
DelveInsight’s Cytomegalovirus Infection Report covers around 20+ products under different phases of clinical development like
-
Late-stage products (Phase III)
-
Mid-stage products (Phase II)
-
Early-stage product (Phase I)
-
Pre-clinical and Discovery stage candidates
-
Discontinued & Inactive candidates
-
Route of Administration
Further Cytomegalovirus Infection product details are provided in the report. Download the Cytomegalovirus Infection pipeline report to learn more about the emerging Cytomegalovirus Infection therapies
Some of the key companies in the Cytomegalovirus Infection Therapeutics Market include:
Key companies developing therapies for Cytomegalovirus Infection are – Merck Sharp & Dohme LLC, Chimerix, VBI Vaccines, Atara Biotherapeutics, SpyBiotech, Moderna, China Immunotech, Nobelpharma, Hookipa Biotech GmbH, Biotest, AlloVir, and others.
Cytomegalovirus Infection Pipeline Analysis:
The Cytomegalovirus Infection pipeline report provides insights into
-
The report provides detailed insights about companies that are developing therapies for the treatment of Cytomegalovirus Infection with aggregate therapies developed by each company for the same.
-
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Cytomegalovirus Infection Treatment.
-
Cytomegalovirus Infection key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
Cytomegalovirus Infection Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
-
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Cytomegalovirus Infection market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Cytomegalovirus Infection drugs and therapies
Cytomegalovirus Infection Pipeline Market Drivers
-
Increasing Prevalence of Cytomegalovirus Infection, increase in Research and developmental Activities are some of the important factors that are fueling the Cytomegalovirus Infection Market.
Cytomegalovirus Infection Pipeline Market Barriers
-
However, high costs associated with the treatment, lack of healthcare infrastructures and other factors are creating obstacles in the Cytomegalovirus Infection Market growth.
Scope of Cytomegalovirus Infection Pipeline Drug Insight
-
Coverage: Global
-
Key Cytomegalovirus Infection Companies: antiviral therapeutics TSRL, Synklino, AlloVir, Moderna, China Immunotech, Nobelpharma, Hookipa Biotech GmbH, Biotest, AlloVir, VBI Vaccines, Lion TCR, Shire, Merck Sharp & Dohme, Takeda, CSL Behring, Chimerix, Novartis, Hookipa Biotech GmbH, and others
-
Key Cytomegalovirus Infection Therapies: Research programme, SYN002, Posoleucel, mRNA-1647, CMV TCR T cell therapy, NPC-21, HB-101, Cytomegalovirus immune globulin, Posoleucel, VBI-1501A, LTV 20, Maribavir, V160, Maribavir, Valganciclovir, Brincidofovir, Everolimus, HB-101 vaccine, and others
-
Cytomegalovirus Infection Therapeutic Assessment: Cytomegalovirus Infection current marketed and Cytomegalovirus Infection emerging therapies
-
Cytomegalovirus Infection Market Dynamics: Cytomegalovirus Infection market drivers and Cytomegalovirus Infection market barriers
Request for Sample PDF Report for Cytomegalovirus Infection Pipeline Assessment and clinical trials
Table of Contents
1. Cytomegalovirus Infection Report Introduction
2. Cytomegalovirus Infection Executive Summary
3. Cytomegalovirus Infection Overview
4. Cytomegalovirus Infection- Analytical Perspective In-depth Commercial Assessment
5. Cytomegalovirus Infection Pipeline Therapeutics
6. Cytomegalovirus Infection Late Stage Products (Phase II/III)
7. Cytomegalovirus Infection Mid Stage Products (Phase II)
8. Cytomegalovirus Infection Early Stage Products (Phase I)
9. Cytomegalovirus Infection Preclinical Stage Products
10. Cytomegalovirus Infection Therapeutics Assessment
11. Cytomegalovirus Infection Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Cytomegalovirus Infection Key Companies
14. Cytomegalovirus Infection Key Products
15. Cytomegalovirus Infection Unmet Needs
16 . Cytomegalovirus Infection Market Drivers and Barriers
17. Cytomegalovirus Infection Future Perspectives and Conclusion
18. Cytomegalovirus Infection Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/